Skip to content

Elderly Falls Prevention With sLiFE Program in Primary Care

Effectiveness of the sLiFE Program to Reduce Falls and Frailty in Elderly People in Primary Care. Randomized Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05912088
Enrollment
650
Registered
2023-06-22
Start date
2023-03-01
Completion date
2025-07-31
Last updated
2023-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Accidental Falls, Activities, Motor, Elderly, Frailty

Brief summary

This study aims to guide older people living in the community on appropriate strategies within a fall prevention program. This program is aimed at training in daily activities carried out through group workshops (guided by a physiotherapist) and at preventing risk situations at home.

Detailed description

Two-arm, non-blind, non-inferiority experimental design. Multicenter, randomized trial. The study tries to assess whether a group intervention following the principles of the sLiFE program is more effective than an usual health advice reducing the incidence of falls.

Interventions

BEHAVIORALIntervention Group

Subjects will participate in groups of about 14 to implement the program.

BEHAVIORALControl Group

Subjects will receive the usual care advice

Sponsors

Fundacion para la Investigacion y Formacion en Ciencias de la Salud
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* People older than 65 years of age * Living at home * Speak and read Spanish

Exclusion criteria

* Heart failure (NYHA class III and IV) * Recent stroke (\<6 months) * Parkinson's disease * In active cancer treatment (last 6 months) * GOLD class III and IV chronic obstructive pulmonary disease * Unstable lower extremity fracture * Amputated lower extremity * Treatment less than 6 months of depression * Uncontrolled resting blood pressure of a systolic \> 160 or diastolic \> 100 or more * Unavailability for intervention, planned travel or relocation more than 2 months within the first 6 months of the study * Moderate to severe cognitive impairment (Mini Mental cognitive assessment \<23) * Current participation in another interventional clinical trial

Design outcomes

Primary

MeasureTime frameDescription
Health effects6 monthsIt will be measured using the quality of life questionnaire EQ-5D
Incidence of falls6 monthsNumber of falls in relation to the degree of physical activity.
Physical activity8 daysIt will be evaluated with a digital pedometer for 9 consecutive days
Frailty6 monthsFrailty will be measured according to the five criteria of Fried's phenotype: 1) Low muscle strength; 2) Poor nutrition; 3) Poor endurance; 4) Slow walking and 5) Low physical activity.

Secondary

MeasureTime frameDescription
Fear of falling6 monthsIt will be assesses using the Short Falls International Scale of Efficacy (Short FES I). It measures of concerns about falling. This scale has 7 items with a Likert scale with 4 options: 1) not at all concerned, 2) somewhat concerned, 3) fairly concerned, and 4) very concerned.
Cognitive assessment6 monthsIt will be evaluated with the Montreal Cognitive Assessment (MoCA): 30 questions and takes 10-12 minutes to complete.
Motor function6 monthsIt will be evaluated with the Short Physical Performance Battery (SPPB). It assesses three aspects of mobility: balance, gait speed and strength of limbs or lower limbs to get up from a chair
Adherence to exercise6 monthsIt will be assessed using the Exercise Adherence Rating Scale (EARS). It is composed of 16 items scored using a 5-point Likert scale (0 = completely agree to 4 = completely disagree) with a possible summed score range from 0 to 64.

Countries

Spain

Contacts

Primary ContactEmiliano Rodríguez-Sánchez, Dr
emiliano@usal.es923231859
Backup ContactLuis García-Ortiz, Dr
lgarciao@usal.es635542886

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026